ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1207

Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid

Huan Meng1, Steven H Lam2, Ho So1 and Lai-shan Tam3, 1The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, 2The Chinese university of Hong Kong, Hong Kong, Hong Kong, 3The Chinese University of Hong Kong, Hong Kong, China

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Inflammation, Psoriatic arthritis, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory burden (c-reactive protein [CRP] and erythrocyte sedimentation rate [ESR] levels) and drugs used to suppress inflammation (disease-modifying anti-rheumatic drugs [DMARDs], non-steroidal anti-inflammatory drugs [NSAIDs]) and steroid over time are independently associated with major cardiovascular events (MACE) in patients with IA.

Methods: A population-based cohort of IA patients was identified in the citywide database of the Hong Kong Hospital Authority. IA patients recruited from Jan 2006 to Dec 2015 were followed until the end of 2018. The outcome was the occurrence of a first MACE, defined as unstable angina, acute myocardial infarction, stroke/transient ischemic attack, or death from cardiovascular causes. Cox proportional hazard models with time-varying CRP and ESR levels and drugs used were analyzed to identify the risk of having MACE in IA patients.

Results: A total of 13,905 (12,233 RA patients, 1,672 PsA patients) patients with IA were recruited (Table 1), with 119,571 patient-years follow-up. 934 (7.0 %) patients developed a first MACE. At baseline, the MACE+ve group were older (68.9±11.8 vs 56.0±14.2, p< 0.001), had more traditional cardiovascular risk factors, higher levels of CRP (2.6±3.2 vs 1.6±2.4, p< 0.001) and ESR (58.8±32.2 vs 42.5±29.6, p< 0.001), more exposure to steroid (43.4% vs 33.7%, p< 0.001) and less exposure to anti-tumor necrosis factor inhibitors (anti-TNF) (1.0% vs 2.8%, p< 0.001), methotrexate (MTX) (46.5% vs 56.1%, p< 0.001), COXII inhibitors (COXIIi) (3.6% vs 7.0%, p< 0.001), non-selective NSAIDs (nsNSAIDs) (63.7% vs 70.6%, p< 0.001) compared to MACE-ve group (Table 2). After adjusting for age, sex, traditional cardiovascular comorbidities using multivariable cox regression analysis, higher inflammatory burden (as reflected by the time-varying ESR levels [hazard ratio {HR} 1.01, 95% confidence interval {CI} 1.01-1.01, p< 0.001] in RA and [HR 1.02, 95%CI 1.01-1.03, p< 0.001] in PsA), time-varying CRP ([HR 1.12, 95% CI 1.10-1.13, p< 0.001] in RA and [HR 1.16, 95% CI 1.11-1.21, p< 0.001] in PsA) and the use of steroid ([HR 1.72-1.80] in RA and [HR 1.93-2.39] in PsA) were independently associated with a higher risk of developing MACE. In contrast, exposure to MTX (HR 1.71-1.72), COXIIi (HR 0.58-0.64) and nsNSAIDs (HR 0.82-0.85) had a protective effect against MACE in RA cohort in the multivariate model. While biologic DMARDs were not associated with MACE in both RA and PsA (Table 3).

Conclusion: Increased inflammatory burden as reflected by elevated ESR and CRP level over time, and increased exposure to steroid were independently associated with increased risk of MACE in IA, while the risk was significantly reduced with MTX and NSAIDs use in RA patients.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: H. Meng, None; S. Lam, None; H. So, None; L. Tam, AbbVie, Amgen, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Sanofi, AstraZeneca.

To cite this abstract in AMA style:

Meng H, Lam S, So H, Tam L. Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/risk-factors-for-major-cardiovascular-events-mace-in-inflammatory-arthritis-a-time-dependent-analysis-on-the-inflammatory-burden-use-of-dmards-nsaids-and-steroid/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-major-cardiovascular-events-mace-in-inflammatory-arthritis-a-time-dependent-analysis-on-the-inflammatory-burden-use-of-dmards-nsaids-and-steroid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology